Lunresertib is under clinical development by Repare Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lunresertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Lunresertib in Endometrial Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lunresertib overview

Lunresertib (RP-6306) is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer, esophageal cancer, cholangiocarcinoma, breast cancer, head and neck cancer, soft tissue sarcoma, bladder cancer, cervical cancer, gastrointestinal stromal tumor (gist), melanoma, gallbladder cancer, vulvar cancer, sarcomas. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.

Repare Therapeutics overview

Repare Therapeutics is a clinical-stage precision oncology company. Its products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutic utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company operates under the brand SNIPRx. It operates in the US and Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.

For a complete picture of Lunresertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.